

# Response Form to the Consultation Paper

## ESMA fees for DRSP



## Responding to this paper

ESMA invites comments on all matters in this paper and in particular on the specific questions summarised in Annex 1. Comments are most helpful if they:

1. respond to the question stated;
2. indicate the specific question to which the comment relates;
3. contain a clear rationale; and
4. describe any alternatives ESMA should consider.

ESMA will consider all comments received by **4 January 2021**.

All contributions should be submitted online at [www.esma.europa.eu](http://www.esma.europa.eu) under the heading 'Your input - Consultations'.

### Instructions

In order to facilitate analysis of responses to the Consultation Paper, respondents are requested to follow the below steps when preparing and submitting their response:

1. Insert your responses to the questions in the Consultation Paper in the present response form.
2. Please do not remove tags of the type <ESMA\_QUESTION\_CP\_DRFE\_1>. Your response to each question has to be framed by the two tags corresponding to the question.
3. If you do not wish to respond to a given question, please do not delete it but simply leave the text "TYPE YOUR TEXT HERE" between the tags.
4. When you have drafted your response, name your response form according to the following convention: ESMA\_DRFE\_nameofrespondent\_RESPONSEFORM. For example, for a respondent named ABCD, the response form would be entitled ESMA\_ DRFE \_ABCD\_RESPONSEFORM.
5. Upload the form containing your responses, in Word format, to ESMA's website ([www.esma.europa.eu](http://www.esma.europa.eu) under the heading "Your input – Open Consultations" → "Public Consultation on fees for data reporting service providers (DRSP)").

### **Publication of responses**

All contributions received will be published following the close of the consultation, unless you request otherwise. Please clearly and prominently indicate in your submission any part you do not wish to be publicly disclosed. A standard confidentiality statement in an email message will not be treated as a request for non-disclosure. A confidential response may be requested from us in accordance with ESMA's rules on access to documents. We may consult you if we receive such a request. Any decision we make not to disclose the response is reviewable by ESMA's Board of Appeal and the European Ombudsman.

### **Data protection**

Information on data protection can be found at [www.esma.europa.eu](http://www.esma.europa.eu) under the heading [Legal Notice](#).

### **Who should read this paper?**

This consultation is looking for feedback from data reporting services providers, market participants and authorities.

## General information about respondent

Name of the company / organisation	Wiener Börse AG
Activity	Regulated markets/Exchanges/Trading Systems
Are you representing an association?	<input type="checkbox"/>
Country/Region	Austria

## Introduction

***Please make your introductory comments below, if any***

<ESMA\_COMMENT\_CP\_DRFE\_1>

TYPE YOUR TEXT HERE

<ESMA\_COMMENT\_CP\_DRFE\_1>

## Questions

**Q1: Do you agree with the proposed approach for DRSP fees? Please elaborate in detail the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_1>

Yes – the DRSP fees have a clear structure

<ESMA\_QUESTION\_DRFE\_1>

**Q2: Do you agree with the proposed application fee for ARMs and APAs? Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_2>

No – the application fee for ARMs and APAs must be on a similar level like the local application fee in each country of the EU.

<ESMA\_QUESTION\_DRFE\_2>

**Q3: Do you agree with the proposed authorisation fee for ARMs and APAs? Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_3>

No – the authorisation fee for ARMs and APAs must be on a similar level like the local authorisation in each country of the EU.

<ESMA\_QUESTION\_DRFE\_3>

**Q4: Do you agree with the reduced additional application and authorisation fee for each additional DRSP type in the case of a simultaneous application? Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_4>

Yes – the additional application fees for APA and ARM must be lower than the main application fee

<ESMA\_QUESTION\_DRFE\_4>

**Q5: Do you agree with the proposed application and authorisation fee for CTP?  
Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_5>

Maybe the fee for CTP's should have the same level like for an APA or ARM because to reach a positive business case for a CTP is much higher than for an APA or ARM.

<ESMA\_QUESTION\_DRFE\_5>

**Q6: Do you agree with the proposed approach to calculate first-year fees for DRSPs authorised by ESMA under MiFIR? Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_6>

Yes – the introduction of the number of calendar days from the date of authorisation until 31 December makes sense.

<ESMA\_QUESTION\_DRFE\_6>

**Q7: Do you agree with the proposed approach for the calculation of annual fees for DRSPs supervised by ESMA? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_7>

Yes – there must be a clear transparency and predictability of the annual fees for DRSP's

<ESMA\_QUESTION\_DRFE\_7>

**Q8: Do you agree with the use of revenues for the purposes of calculation of the applicable turnover? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_8>

Yes – there must be a clear separation between large and smaller APA's and ARM's to protect the fair competition in the EU.

<ESMA\_QUESTION\_DRFE\_8>

**Q9: With regards to the revenues, do you agree with including both revenues from core and ancillary services? How complex is to identify and report the revenues from ancillary services attributable to each data reporting service separately? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_9>

No – there must be a clear separation between large and smaller APA's and ARM's to protect the fair competition in the EU and revenues from ancillary services should not be part of this calculation.

<ESMA\_QUESTION\_DRFE\_9>

**Q10: In those cases, where ancillary services cannot be directly allocated to each data reporting service, do you agree with allocating them in accordance with the revenues from the respective core services? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_10>

No – there must be a clear separation between large and smaller APA's and ARM's to protect the fair competition in the EU and revenues from ancillary services should not be part of this calculation.

<ESMA\_QUESTION\_DRFE\_10>

**Q11: Do you agree with the proposed level of minimum supervisory fee? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_11>

No – the supervisory fee for ARMs and APAs must be on a similar level like the local supervisory fee in each country of the EU.

<ESMA\_QUESTION\_DRFE\_11>

**Q12: Do you agree with the proposed level of minimum supervisory fees in case more than one data reporting service is provided? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_12>

TYPE YOUR TEXT HERE

<ESMA\_QUESTION\_DRFE\_12>

**Q13: Do you agree with the approach for determining the fees in 2022 for already authorised DRSPs? Are there any difficulties in identifying the revenues from data reporting services provided in 2020? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_13>

yes

<ESMA\_QUESTION\_DRFE\_13>

**Q14: Do you agree with the proposed approach for the supervisory fees related to preparatory work? Please elaborate.**

<ESMA\_QUESTION\_DRFE\_14>

No – there must be a clear fee structure for the next years and the future and not an extra fee for the years 2020 and 2021! Each DRSP has paid the yearly supervisory fee directly to its NCA during these years!

<ESMA\_QUESTION\_DRFE\_14>

**Q15: Do you agree with the proposal for the payment conditions by DRSPs of the fees for application, authorisation or extension of authorisation under MIFIR? Please elaborate on the reasons for your answer.**

<ESMA\_QUESTION\_DRFE\_15>

yes

<ESMA\_QUESTION\_DRFE\_15>

**Q16: Do you agree with the proposal to not reimburse DRSPs in case they decide to withdraw their application for authorisation or extension of authorisation before authorisation is granted? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_16>

TYPE YOUR TEXT HERE

<ESMA\_QUESTION\_DRFE\_16>

**Q17: Do you agree with the proposal that DRSPs pay their annual fees by 31 March of the year for which the fees are due? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_17>

yes

<ESMA\_QUESTION\_DRFE\_17>

**Q18: Do you agree with the proposal for the timing of payment of the 2022 fees? Please elaborate on the reasons for your response.**

<ESMA\_QUESTION\_DRFE\_18>

yes

<ESMA\_QUESTION\_DRFE\_18>

ESMA • 201-203 rue de Bercy • CS 80910 • 75589 Paris Cedex 12 • France • Tel. +33 (0) 1 58 36 43 21 • [www.esma.europa.eu](http://www.esma.europa.eu)